No profile data available.
K Pharma,Inc. (4896.T) is a healthcare company in the brain and nerve treatment drugs industry, based in Minato, Japan, with about 20 full-time employees.
It reported revenue of 0 JPY for fiscal year 2025, and net income of -993.23 million JPY. Its market capitalization was 8.75 billion JPY as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions.
K Pharma,Inc. reported 0 JPY in revenue for fiscal year 2025.
8.75 billion JPY as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include SanBio Company Limited (4592.T), Oncolys BioPharma Inc. (4588.T), Kringle Pharma, Inc. (4884.T), MedRx Co., Ltd (4586.T).